In-vitro antimicrobial susceptibility of Neisseria gonorrhoeae in New Zealand.

Abstract

SUMMARY Four hundred and forty-two isolates of Neisseria gonorrhoeae were tested by an agar dilution method for their susceptibility to penicillin, ampicillin, tetracycline, cephaloridine, and spectinomycin. Of these isolates, 295 were tested for their susceptibility to sulphamethoxazole and to trimethoprim by the same method, using Oxoid diagnostic sensitivity test agar plus 7'5 % laked horse blood instead of Proteose No. 3 agar plus 1 % IsoVitaleX and 1 % haemoglobin. One hundred (22'6%) of the isolates were found to be relatively resistant to penicillin (minimum inhibitory concentration (MIC)>0 1 iu/ml), but only 11 % had a MIC of 1 iu/ml or higher. Ampicillin was slightly more active than penicillin in that all isolates were inhibited by 0 5 tg/ml or less. For 3 7 % of isolates the MIC of tetracycline was 2 Vg/ml or higher. All isolates were sensitive to spectinomycin.By calculating the Spearman rank correlation coefficient (rs), a high correlation (rs>0 5) was found between susceptibility to penicillin and susceptibility to ampicillin, tetracycline, and cephaloridine. Low correlation (rs<0 2) was found between susceptibility to penicillin and susceptibility to spectinomycin, sulphamethoxazole, and trimethoprim.

DNAJC12 as a Mediator Between ESR1 and ERBB4 in Breast Carcinoma Cells

“…In this study, 1,108 invasive breast carcinoma samples from the TCGA database were used to identify genes correlated with ESR1, DNAJC12, and ERBB4. According to the key genes of signal pathways provided by the cBioPortal, the VBA program was used to screen the genes having a correlation with DNAJC12 ( 45 ). Then, PCR detection was employed to verify differential expression of the identified genes.…”

Invasive pneumococcal disease in New Zealand 1998–2005: capsular serotypes and antimicrobial resistance

“…National surveillance of invasive pneumococcal disease (IPD) in New Zealand is laboratory based, and provides data on the epidemiology of the disease, distribution of serotypes and antimicrobial susceptibility [1–4]. These data contribute to the development of policies to prevent and treat pneumococcal disease, including immunization policy and guidelines for empirical therapy.…”